Review



cd34 cd38 cell isolation kit  (Miltenyi Biotec)


Bioz Verified Symbol Miltenyi Biotec is a verified supplier
Bioz Manufacturer Symbol Miltenyi Biotec manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 95

    Structured Review

    Miltenyi Biotec cd34 cd38 cell isolation kit
    Cd34 Cd38 Cell Isolation Kit, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 95/100, based on 3 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/cd34+cell+isolation+kit/CD34%2BCD38-+Cell+Isolation+Kit%2C+human/pm41809821-64-12-18
    Average 95 stars, based on 3 article reviews
    cd34 cd38 cell isolation kit - by Bioz Stars, 2026-09
    95/100 stars

    Images

    Related Articles

    Irradiation:

    Article Title: BTG2-deficient mast cells remodel the tumor and tumor-draining lymph node microenvironment leading to chemotherapy resistance in breast cancer.
    Article Snippet: .. Briefly, 3-4 week female NSG mice were subjected to 2 cGy total body irradiation 12 hr before tail vein injection with 2×105 CD34+ cells isolated from PBMCs by direct CD34 Cell Isolation Kit (Cat# 130- 046-702, Miltenyi Biotec). ..

    Article Title: BTG2-deficient mast cells remodel the tumor and tumor-draining lymph node microenvironment leading to chemotherapy resistance in breast cancer
    Article Snippet: .. Briefly, 3-4 week female NSG mice were subjected to 2 cGy total body irradiation 12 hr before tail vein injection with 2×10 5 CD34+ cells isolated from PBMCs by direct CD34 Cell Isolation Kit (Cat# 130-046-702, Miltenyi Biotec). ..

    Injection:

    Article Title: BTG2-deficient mast cells remodel the tumor and tumor-draining lymph node microenvironment leading to chemotherapy resistance in breast cancer.
    Article Snippet: .. Briefly, 3-4 week female NSG mice were subjected to 2 cGy total body irradiation 12 hr before tail vein injection with 2×105 CD34+ cells isolated from PBMCs by direct CD34 Cell Isolation Kit (Cat# 130- 046-702, Miltenyi Biotec). ..

    Article Title: BTG2-deficient mast cells remodel the tumor and tumor-draining lymph node microenvironment leading to chemotherapy resistance in breast cancer
    Article Snippet: .. Briefly, 3-4 week female NSG mice were subjected to 2 cGy total body irradiation 12 hr before tail vein injection with 2×10 5 CD34+ cells isolated from PBMCs by direct CD34 Cell Isolation Kit (Cat# 130-046-702, Miltenyi Biotec). ..

    Isolation:

    Article Title: BTG2-deficient mast cells remodel the tumor and tumor-draining lymph node microenvironment leading to chemotherapy resistance in breast cancer.
    Article Snippet: .. Briefly, 3-4 week female NSG mice were subjected to 2 cGy total body irradiation 12 hr before tail vein injection with 2×105 CD34+ cells isolated from PBMCs by direct CD34 Cell Isolation Kit (Cat# 130- 046-702, Miltenyi Biotec). ..

    Article Title: Ultralow-dose binary oncolytic/helper-dependent adenovirus promotes antitumor activity in preclinical and clinical studies
    Article Snippet: .. CD34 + cells were isolated using a CD34 + cell isolation kit (Miltenyi Biotec Inc.) and expanded with StemSpan CD34 + Expansion Supplementation for 3 days (STEMCELL Technologies). ..

    Article Title: Oncolytic adeno-immunotherapy improves allogeneic adoptive HER2.CAR-NK function against pancreatic ductal adenocarcinoma
    Article Snippet: For the humanized mouse model, newborn (1–2 days from birth) female and male NSGSGM3 (NSGTGCMV-IL3, CSF2, KITLG Eav/mloySz; Jackson Laboratory) were sublethally irradiated (100 cGy) and intrahepatically injected with 5 × 10 4 human cord blood unit (CBU)-derived CD34 + cells. .. CBUs were obtained from MD Anderson Stem Cell Center, and CD34 + cells were isolated using CD34 + cell isolation kit (Miltenyi Biotech Inc.). ..

    Article Title: Droplet digital polymerase chain reaction-based quantitation of therapeutic lentiviral vector copies in transduced hematopoietic stem cells.
    Article Snippet: Background aims: Gene therapy using lentiviral vectors (LVs) that harbor a functional b-globin gene provides a curative treatment for hemoglobinopathies including beta-thalassemia and sickle cell disease.. Accurate quantification of the vector copy number (VCN) and/or the proportion of transduced cells is critical to evaluate the efficacy of transduction and stability of the transgene during treatment.. Moreover, commonly used techniques for LV quantification, including real-time quantitative polymerase chain reaction (PCR) or fluorescence-activated cell sorting, require either a standard curve or expression of a reporter protein for the detection of transduced cells.

    Article Title: Oncolytic Adeno-immunotherapy Improves Allogeneic Adoptive HER2.CAR-NK Function Against Pancreatic Ductal Adenocarcinoma
    Article Snippet: For the humanized mouse model, newborn (1–2 days from birth) female and male NSGSGM3 (NSGTGCMV-IL3, CSF2, KITLG Eav/mloySz; Jackson Laboratory) were sublethally irradiated (100 cGy) and intrahepatically injected with 5 × 104 human cord blood unit (CBU)-derived CD34+ cells. .. CBUs were obtained from MD Anderson Stem Cell Center, and CD34+ cells were isolated using CD34+ cell isolation kit (Miltenyi Biotech Inc.). ..

    Article Title: BTG2-deficient mast cells remodel the tumor and tumor-draining lymph node microenvironment leading to chemotherapy resistance in breast cancer
    Article Snippet: .. Briefly, 3-4 week female NSG mice were subjected to 2 cGy total body irradiation 12 hr before tail vein injection with 2×10 5 CD34+ cells isolated from PBMCs by direct CD34 Cell Isolation Kit (Cat# 130-046-702, Miltenyi Biotec). ..

    Article Title: Ultralow-dose binary oncolytic/helper-dependent adenovirus promotes antitumor activity in preclinical and clinical studies.
    Article Snippet: .. CD34+ cells were isolated using a CD34+ cell isolation kit (Miltenyi Biotec Inc.) and expanded with StemSpan CD34+ Expansion Supplementation for 3 days (STEMCELL Technologies). ..

    Cell Isolation:

    Article Title: BTG2-deficient mast cells remodel the tumor and tumor-draining lymph node microenvironment leading to chemotherapy resistance in breast cancer.
    Article Snippet: .. Briefly, 3-4 week female NSG mice were subjected to 2 cGy total body irradiation 12 hr before tail vein injection with 2×105 CD34+ cells isolated from PBMCs by direct CD34 Cell Isolation Kit (Cat# 130- 046-702, Miltenyi Biotec). ..

    Article Title: Ultralow-dose binary oncolytic/helper-dependent adenovirus promotes antitumor activity in preclinical and clinical studies
    Article Snippet: .. CD34 + cells were isolated using a CD34 + cell isolation kit (Miltenyi Biotec Inc.) and expanded with StemSpan CD34 + Expansion Supplementation for 3 days (STEMCELL Technologies). ..

    Article Title: Anti-IL1RAP antibodies and their use for treating humans
    Article Snippet: .. Mononuclear cells (MNCs) were separated using LymphoprepTM (Axis-Shield PoC AS, Oslo, Norway) according to the manufacturer's instructions and CD34+ cells were enriched using the CD34+ cell isolation kit (Miltenyi Biotech, Bergisch Gladbach, Germany) as previously described22, on a regular basis, this yielded a purity of CD34+ cells above 95%. ..

    Article Title: Oncolytic adeno-immunotherapy improves allogeneic adoptive HER2.CAR-NK function against pancreatic ductal adenocarcinoma
    Article Snippet: For the humanized mouse model, newborn (1–2 days from birth) female and male NSGSGM3 (NSGTGCMV-IL3, CSF2, KITLG Eav/mloySz; Jackson Laboratory) were sublethally irradiated (100 cGy) and intrahepatically injected with 5 × 10 4 human cord blood unit (CBU)-derived CD34 + cells. .. CBUs were obtained from MD Anderson Stem Cell Center, and CD34 + cells were isolated using CD34 + cell isolation kit (Miltenyi Biotech Inc.). ..

    Article Title: Droplet digital polymerase chain reaction-based quantitation of therapeutic lentiviral vector copies in transduced hematopoietic stem cells.
    Article Snippet: Background aims: Gene therapy using lentiviral vectors (LVs) that harbor a functional b-globin gene provides a curative treatment for hemoglobinopathies including beta-thalassemia and sickle cell disease.. Accurate quantification of the vector copy number (VCN) and/or the proportion of transduced cells is critical to evaluate the efficacy of transduction and stability of the transgene during treatment.. Moreover, commonly used techniques for LV quantification, including real-time quantitative polymerase chain reaction (PCR) or fluorescence-activated cell sorting, require either a standard curve or expression of a reporter protein for the detection of transduced cells.

    Article Title: Oncolytic Adeno-immunotherapy Improves Allogeneic Adoptive HER2.CAR-NK Function Against Pancreatic Ductal Adenocarcinoma
    Article Snippet: For the humanized mouse model, newborn (1–2 days from birth) female and male NSGSGM3 (NSGTGCMV-IL3, CSF2, KITLG Eav/mloySz; Jackson Laboratory) were sublethally irradiated (100 cGy) and intrahepatically injected with 5 × 104 human cord blood unit (CBU)-derived CD34+ cells. .. CBUs were obtained from MD Anderson Stem Cell Center, and CD34+ cells were isolated using CD34+ cell isolation kit (Miltenyi Biotech Inc.). ..

    Article Title: BTG2-deficient mast cells remodel the tumor and tumor-draining lymph node microenvironment leading to chemotherapy resistance in breast cancer
    Article Snippet: .. Briefly, 3-4 week female NSG mice were subjected to 2 cGy total body irradiation 12 hr before tail vein injection with 2×10 5 CD34+ cells isolated from PBMCs by direct CD34 Cell Isolation Kit (Cat# 130-046-702, Miltenyi Biotec). ..

    Article Title: Ultralow-dose binary oncolytic/helper-dependent adenovirus promotes antitumor activity in preclinical and clinical studies.
    Article Snippet: .. CD34+ cells were isolated using a CD34+ cell isolation kit (Miltenyi Biotec Inc.) and expanded with StemSpan CD34+ Expansion Supplementation for 3 days (STEMCELL Technologies). ..



    Similar Products

    95
    Miltenyi Biotec cd34 cd38 cell isolation kit
    Cd34 Cd38 Cell Isolation Kit, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/cd34+cell+isolation+kit/CD34%2BCD38-+Cell+Isolation+Kit%2C+human/pm41809821-64-12-18
    Average 95 stars, based on 1 article reviews
    cd34 cd38 cell isolation kit - by Bioz Stars, 2026-09
    95/100 stars
      Buy from Supplier

    97
    Miltenyi Biotec cd34 cell isolation
    a Diagram of patients who underwent UCBT. Patients were divided into two groups on the basis of <t>stem</t> <t>cell</t> infusion timing, with a cutoff time of 9:40 am. UCBT, unrelated cord blood transplantation; CR, complete remission; MRD minimal residual disease; CB, cord blood. b Histogram showing the distribution of stem cell infusion times in the cohort. c , d Cumulative incidence (CI) of grade II-IV aGVHD ( c ) ( P = 0.416) and grade III-IV aGVHD ( d ) ( P = 0.004) in the earlier infusion (≤ 9:40 am, n = 219) and later infusion (> 9:40 am, n = 215) groups. The P values are two-sided and reported as exact values. e CI of overall chronic GVHD (cGVHD) in the earlier infusion (≤ 9:40 am) and later infusion (> 9:40 am) groups ( P = 0.276). The P values are two-sided and reported as exact values. f CI of 3-year TRM in the earlier infusion (≤ 9:40 am, n = 219) and later infusion (> 9:40 am, n = 215) groups ( P = 0.067). The P values are two-sided and reported as exact values. g – i Probabilities of overall survival ( g ) ( P = 0.022), disease-free survival ( h ) ( P = 0.050), and GRFS ( i ) ( P < 0.001) in the earlier infusion (≤ 9:40 am, n = 219) and later infusion (> 9:40 am, n = 215) groups. j CI of 3-year relapse in the earlier infusion (≤ 9:40 am, n = 219) and later infusion (> 9:40 am, n = 215) groups ( P = 0.775). The P values are two-sided and reported as exact values.The data were analyzed by Gray’s test ( c – f , and j ) and the log-rank test ( g – i ). Source data are provided as a Source Data file.
    Cd34 Cell Isolation, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 97/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/cd34+cell+isolation+kit/CD34+MicroBead+Kit%2C+human/pmc12960979-313-1-12
    Average 97 stars, based on 1 article reviews
    cd34 cell isolation - by Bioz Stars, 2026-09
    97/100 stars
      Buy from Supplier

    97
    Miltenyi Biotec direct cd34 progenitor cell isolation kit
    a Diagram of patients who underwent UCBT. Patients were divided into two groups on the basis of <t>stem</t> <t>cell</t> infusion timing, with a cutoff time of 9:40 am. UCBT, unrelated cord blood transplantation; CR, complete remission; MRD minimal residual disease; CB, cord blood. b Histogram showing the distribution of stem cell infusion times in the cohort. c , d Cumulative incidence (CI) of grade II-IV aGVHD ( c ) ( P = 0.416) and grade III-IV aGVHD ( d ) ( P = 0.004) in the earlier infusion (≤ 9:40 am, n = 219) and later infusion (> 9:40 am, n = 215) groups. The P values are two-sided and reported as exact values. e CI of overall chronic GVHD (cGVHD) in the earlier infusion (≤ 9:40 am) and later infusion (> 9:40 am) groups ( P = 0.276). The P values are two-sided and reported as exact values. f CI of 3-year TRM in the earlier infusion (≤ 9:40 am, n = 219) and later infusion (> 9:40 am, n = 215) groups ( P = 0.067). The P values are two-sided and reported as exact values. g – i Probabilities of overall survival ( g ) ( P = 0.022), disease-free survival ( h ) ( P = 0.050), and GRFS ( i ) ( P < 0.001) in the earlier infusion (≤ 9:40 am, n = 219) and later infusion (> 9:40 am, n = 215) groups. j CI of 3-year relapse in the earlier infusion (≤ 9:40 am, n = 219) and later infusion (> 9:40 am, n = 215) groups ( P = 0.775). The P values are two-sided and reported as exact values.The data were analyzed by Gray’s test ( c – f , and j ) and the log-rank test ( g – i ). Source data are provided as a Source Data file.
    Direct Cd34 Progenitor Cell Isolation Kit, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 97/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/cd34+cell+isolation+kit/CD34+MicroBead+Kit%2C+human/pm41288024-53-49-56
    Average 97 stars, based on 1 article reviews
    direct cd34 progenitor cell isolation kit - by Bioz Stars, 2026-09
    97/100 stars
      Buy from Supplier

    97
    Miltenyi Biotec human cd34 progenitor cell isolation kit
    a Diagram of patients who underwent UCBT. Patients were divided into two groups on the basis of <t>stem</t> <t>cell</t> infusion timing, with a cutoff time of 9:40 am. UCBT, unrelated cord blood transplantation; CR, complete remission; MRD minimal residual disease; CB, cord blood. b Histogram showing the distribution of stem cell infusion times in the cohort. c , d Cumulative incidence (CI) of grade II-IV aGVHD ( c ) ( P = 0.416) and grade III-IV aGVHD ( d ) ( P = 0.004) in the earlier infusion (≤ 9:40 am, n = 219) and later infusion (> 9:40 am, n = 215) groups. The P values are two-sided and reported as exact values. e CI of overall chronic GVHD (cGVHD) in the earlier infusion (≤ 9:40 am) and later infusion (> 9:40 am) groups ( P = 0.276). The P values are two-sided and reported as exact values. f CI of 3-year TRM in the earlier infusion (≤ 9:40 am, n = 219) and later infusion (> 9:40 am, n = 215) groups ( P = 0.067). The P values are two-sided and reported as exact values. g – i Probabilities of overall survival ( g ) ( P = 0.022), disease-free survival ( h ) ( P = 0.050), and GRFS ( i ) ( P < 0.001) in the earlier infusion (≤ 9:40 am, n = 219) and later infusion (> 9:40 am, n = 215) groups. j CI of 3-year relapse in the earlier infusion (≤ 9:40 am, n = 219) and later infusion (> 9:40 am, n = 215) groups ( P = 0.775). The P values are two-sided and reported as exact values.The data were analyzed by Gray’s test ( c – f , and j ) and the log-rank test ( g – i ). Source data are provided as a Source Data file.
    Human Cd34 Progenitor Cell Isolation Kit, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 97/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/cd34+cell+isolation+kit/CD34+MicroBead+Kit%2C+human/pmc12628175__mmc3-354-29-35
    Average 97 stars, based on 1 article reviews
    human cd34 progenitor cell isolation kit - by Bioz Stars, 2026-09
    97/100 stars
      Buy from Supplier

    94
    Miltenyi Biotec cd34 progenitor cell isolation kit
    a Diagram of patients who underwent UCBT. Patients were divided into two groups on the basis of <t>stem</t> <t>cell</t> infusion timing, with a cutoff time of 9:40 am. UCBT, unrelated cord blood transplantation; CR, complete remission; MRD minimal residual disease; CB, cord blood. b Histogram showing the distribution of stem cell infusion times in the cohort. c , d Cumulative incidence (CI) of grade II-IV aGVHD ( c ) ( P = 0.416) and grade III-IV aGVHD ( d ) ( P = 0.004) in the earlier infusion (≤ 9:40 am, n = 219) and later infusion (> 9:40 am, n = 215) groups. The P values are two-sided and reported as exact values. e CI of overall chronic GVHD (cGVHD) in the earlier infusion (≤ 9:40 am) and later infusion (> 9:40 am) groups ( P = 0.276). The P values are two-sided and reported as exact values. f CI of 3-year TRM in the earlier infusion (≤ 9:40 am, n = 219) and later infusion (> 9:40 am, n = 215) groups ( P = 0.067). The P values are two-sided and reported as exact values. g – i Probabilities of overall survival ( g ) ( P = 0.022), disease-free survival ( h ) ( P = 0.050), and GRFS ( i ) ( P < 0.001) in the earlier infusion (≤ 9:40 am, n = 219) and later infusion (> 9:40 am, n = 215) groups. j CI of 3-year relapse in the earlier infusion (≤ 9:40 am, n = 219) and later infusion (> 9:40 am, n = 215) groups ( P = 0.775). The P values are two-sided and reported as exact values.The data were analyzed by Gray’s test ( c – f , and j ) and the log-rank test ( g – i ). Source data are provided as a Source Data file.
    Cd34 Progenitor Cell Isolation Kit, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/cd34+cell+isolation+kit/Diamond+CD34+Isolation+Kit%2C+human/us12453770-1672-33-38
    Average 94 stars, based on 1 article reviews
    cd34 progenitor cell isolation kit - by Bioz Stars, 2026-09
    94/100 stars
      Buy from Supplier

    97
    Miltenyi Biotec human cd34 microbeads kit miltenyi biotec
    a Diagram of patients who underwent UCBT. Patients were divided into two groups on the basis of <t>stem</t> <t>cell</t> infusion timing, with a cutoff time of 9:40 am. UCBT, unrelated cord blood transplantation; CR, complete remission; MRD minimal residual disease; CB, cord blood. b Histogram showing the distribution of stem cell infusion times in the cohort. c , d Cumulative incidence (CI) of grade II-IV aGVHD ( c ) ( P = 0.416) and grade III-IV aGVHD ( d ) ( P = 0.004) in the earlier infusion (≤ 9:40 am, n = 219) and later infusion (> 9:40 am, n = 215) groups. The P values are two-sided and reported as exact values. e CI of overall chronic GVHD (cGVHD) in the earlier infusion (≤ 9:40 am) and later infusion (> 9:40 am) groups ( P = 0.276). The P values are two-sided and reported as exact values. f CI of 3-year TRM in the earlier infusion (≤ 9:40 am, n = 219) and later infusion (> 9:40 am, n = 215) groups ( P = 0.067). The P values are two-sided and reported as exact values. g – i Probabilities of overall survival ( g ) ( P = 0.022), disease-free survival ( h ) ( P = 0.050), and GRFS ( i ) ( P < 0.001) in the earlier infusion (≤ 9:40 am, n = 219) and later infusion (> 9:40 am, n = 215) groups. j CI of 3-year relapse in the earlier infusion (≤ 9:40 am, n = 219) and later infusion (> 9:40 am, n = 215) groups ( P = 0.775). The P values are two-sided and reported as exact values.The data were analyzed by Gray’s test ( c – f , and j ) and the log-rank test ( g – i ). Source data are provided as a Source Data file.
    Human Cd34 Microbeads Kit Miltenyi Biotec, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 97/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/cd34+cell+isolation+kit/NK+Cell+Isolation+Kit%2C+human/pm40803321-1327-105-109
    Average 97 stars, based on 1 article reviews
    human cd34 microbeads kit miltenyi biotec - by Bioz Stars, 2026-09
    97/100 stars
      Buy from Supplier

    Image Search Results


    a Diagram of patients who underwent UCBT. Patients were divided into two groups on the basis of stem cell infusion timing, with a cutoff time of 9:40 am. UCBT, unrelated cord blood transplantation; CR, complete remission; MRD minimal residual disease; CB, cord blood. b Histogram showing the distribution of stem cell infusion times in the cohort. c , d Cumulative incidence (CI) of grade II-IV aGVHD ( c ) ( P = 0.416) and grade III-IV aGVHD ( d ) ( P = 0.004) in the earlier infusion (≤ 9:40 am, n = 219) and later infusion (> 9:40 am, n = 215) groups. The P values are two-sided and reported as exact values. e CI of overall chronic GVHD (cGVHD) in the earlier infusion (≤ 9:40 am) and later infusion (> 9:40 am) groups ( P = 0.276). The P values are two-sided and reported as exact values. f CI of 3-year TRM in the earlier infusion (≤ 9:40 am, n = 219) and later infusion (> 9:40 am, n = 215) groups ( P = 0.067). The P values are two-sided and reported as exact values. g – i Probabilities of overall survival ( g ) ( P = 0.022), disease-free survival ( h ) ( P = 0.050), and GRFS ( i ) ( P < 0.001) in the earlier infusion (≤ 9:40 am, n = 219) and later infusion (> 9:40 am, n = 215) groups. j CI of 3-year relapse in the earlier infusion (≤ 9:40 am, n = 219) and later infusion (> 9:40 am, n = 215) groups ( P = 0.775). The P values are two-sided and reported as exact values.The data were analyzed by Gray’s test ( c – f , and j ) and the log-rank test ( g – i ). Source data are provided as a Source Data file.

    Journal: Nature Communications

    Article Title: Circadian fluctuation of soluble CD26 dictates the impact of the timing of cord blood transplantation on acute graft-versus-host disease

    doi: 10.1038/s41467-026-68958-4

    Figure Lengend Snippet: a Diagram of patients who underwent UCBT. Patients were divided into two groups on the basis of stem cell infusion timing, with a cutoff time of 9:40 am. UCBT, unrelated cord blood transplantation; CR, complete remission; MRD minimal residual disease; CB, cord blood. b Histogram showing the distribution of stem cell infusion times in the cohort. c , d Cumulative incidence (CI) of grade II-IV aGVHD ( c ) ( P = 0.416) and grade III-IV aGVHD ( d ) ( P = 0.004) in the earlier infusion (≤ 9:40 am, n = 219) and later infusion (> 9:40 am, n = 215) groups. The P values are two-sided and reported as exact values. e CI of overall chronic GVHD (cGVHD) in the earlier infusion (≤ 9:40 am) and later infusion (> 9:40 am) groups ( P = 0.276). The P values are two-sided and reported as exact values. f CI of 3-year TRM in the earlier infusion (≤ 9:40 am, n = 219) and later infusion (> 9:40 am, n = 215) groups ( P = 0.067). The P values are two-sided and reported as exact values. g – i Probabilities of overall survival ( g ) ( P = 0.022), disease-free survival ( h ) ( P = 0.050), and GRFS ( i ) ( P < 0.001) in the earlier infusion (≤ 9:40 am, n = 219) and later infusion (> 9:40 am, n = 215) groups. j CI of 3-year relapse in the earlier infusion (≤ 9:40 am, n = 219) and later infusion (> 9:40 am, n = 215) groups ( P = 0.775). The P values are two-sided and reported as exact values.The data were analyzed by Gray’s test ( c – f , and j ) and the log-rank test ( g – i ). Source data are provided as a Source Data file.

    Article Snippet: For CD34+ cell isolation, immunomagnetic depletion was performed via CD34 microbeads (130-046-702, Miltenyi Biotech) following the recommended protocol.

    Techniques: Transplantation Assay